Evidence map›Paper›PMID 39863419›Full record

Trial reportEuropean heart journal. Cardiovascular pharmacotherapy2025

Aspirin vs. clopidogrel monotherapy beyond 1 month after complex percutaneous coronary intervention: a pre-specified subgroup analysis of the STOPDAPT-3 trial.

Takenori Domei, Ko Yamamoto, Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Yuki Obayashi, Ryusuke Nishikawa, Tomoya Kimura, Kenji Ando, Satoru Suwa and 14 more

Registry-linked trialAbstract readClinical Trial, Phase IVComparative StudyMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European heart journal. Cardiovascular pharmacotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04609111 (ShorT and OPtimal Duration of Dual AntiPlatelet Therapy Study After Everolimus-eluting Cobalt-chromium Stent-3), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04609111 phase4unknown statusnot on this map

ShorT and OPtimal Duration of Dual AntiPlatelet Therapy Study After Everolimus-eluting Cobalt-chromium Stent-3

TypeinterventionalSponsorKyoto University, Graduate School of MedicineRan2021 to 2025Enrolled6,002ConditionsAcute Coronary SyndromeArmsNo aspirin, 1-month DAPT
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Takenori DomeiDepartment of Cardiology, Kokura Memorial Hospital, Kitakyushu 802-8555, Japan.
Ko YamamotoDepartment of Cardiology, Kokura Memorial Hospital, Kitakyushu 802-8555, Japan.
Masahiro NatsuakiDepartment of Cardiovascular Medicine, Saga University, Saga 849-0937, Japan.ORCID 0000-0002-0189-2317
Hirotoshi WatanabeDepartment of Cardiology, Hirakata Kohsai Hospital, Hirakata 573-0153, Japan.ORCID 0000-0002-9443-5915
Takeshi MorimotoDepartment of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.ORCID 0000-0002-6844-739X
Yuki ObayashiDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.ORCID 0000-0002-0387-8877
Ryusuke NishikawaDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.
Tomoya KimuraDepartment of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya 663-8501, Japan.
Kenji AndoDepartment of Cardiology, Kokura Memorial Hospital, Kitakyushu 802-8555, Japan.
Satoru SuwaDepartment of Cardiology, Juntendo University Shizuoka Hospital, Izunokuni 410-2211, Japan.
Tsuyoshi IsawaDepartment of Cardiology, Sendai Kousei Hospital, Sendai 981-0914, Japan.ORCID 0000-0003-1271-0344
Hiroyuki TakenakaDepartment of Cardiology, Hirakata Kohsai Hospital, Hirakata 573-0153, Japan.
Tetsuya IshikawaDepartment of Cardiology, Dokkyo Medical University Saitama Medical Center, Koshigaya 343-0845, Japan.
Toshihiro TamuraDepartment of Cardiology, Tenri Hospital, Tenri 632-8552, Japan.
Kando KawahatsuDepartment of Cardiology, Teine Keijinkai Hospital, Teine 006-0811, Japan.
Fujio HayashiDepartment of Cardiovascular Center, Japanese Red Cross Osaka Hospital, Osaka 543-8555,  Japan.
Mitsuru AbeDepartment of Cardiology, Kyoto Medical Center, Kyoto 612-0861, Japan.
Takeshi SerikawaDepartment of Cardiology, Fukuoka Wajiro Hospital, Fukuoka 811-0213, Japan.
Hiroyoshi MoriShowa University Fujigaoka Hospital, Yokohama 227-8501, Japan.ORCID 0000-0001-6060-3485
Takayuki KawamuraDepartment of Cardiology, Kindai University Faculty of Medicine, Osakasayama 589-8511, Japan.
Arata HagikuraDivision of Cardiology, Tsukazaki Hospital, Himeji 671-1227, Japan.
Naoki ShibataOgaki Municipal Hospital, Ogaki 503-8502, Japan.
Koh OnoDepartment of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.ORCID 0000-0002-4163-980X
Takeshi KimuraDepartment of Cardiology, Hirakata Kohsai Hospital, Hirakata 573-0153, Japan.ORCID 0000-0002-5665-4076

Funding

Abbott Medical Japan
6 · The paper itself

Abstract

aimsThere were no previous studies comparing aspirin vs. P2Y12 inhibitor monotherapy following short dual antiplatelet therapy (DAPT) after complex percutaneous coronary intervention (PCI). METHODS AND

resultsWe conducted a pre-specified subgroup analysis based on complex PCI in the 1-year results of the STOPDAPT-3 (ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3) trial, which randomly compared 1-month DAPT followed by aspirin monotherapy (aspirin group) with 1-month prasugrel monotherapy followed by clopidogrel monotherapy (clopidogrel group). The main analysis in the present study was the 30-day landmark analysis. The co-primary endpoints were cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or stroke) and major bleeding (Bleeding Academic Research Consortium 3 or 5). In the 30-day landmark analysis (N = 5833), there were 1415 patients (24.3%) who underwent complex PCI. There was a significant interaction between complex PCI and the effect of the aspirin group relative to the clopidogrel group for cardiovascular events (complex PCI: 3.3% vs. 5.2%, non-complex PCI: 4.3% vs. 3.6%, interaction P = 0.04) and net adverse clinical events (complex PCI: 4.8% vs. 7.2%, non-complex PCI: 5.3% vs. 4.4%, interaction P = 0.02), but not for bleeding events (complex PCI: 2.1% vs. 2.7%, non-complex PCI: 1.7% vs. 1.4%, interaction P = 0.35).

conclusionsThere was a significant interaction between complex PCI and the effect of aspirin monotherapy relative to clopidogrel monotherapy beyond 1 month and up to 1 year for cardiovascular events due to numerically lower risk of aspirin monotherapy in patients with complex PCI, while the effect of aspirin monotherapy relative to clopidogrel monotherapy was not different for bleeding regardless of complex PCI. CLINICAL

trial registrationShorT and OPtimal duration of Dual AntiPlatelet Therapy after everolimus-eluting cobalt-chromium stent-3 [STOPDAPT-3]; NCT04609111.

Indexed as

AspirinClopidogrelCoronary Artery DiseaseDual Anti-Platelet TherapyPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAgedDrug Administration ScheduleFemaleHemorrhageHumansMaleMiddle AgedPrasugrel HydrochlorideRisk AssessmentAspirinClopidogrelPlatelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsAntiplatelet therapyCoronary stentPercutaneous coronary interventionProcedural complexity

Identifiers

PMID39863419
PMCPMC11905749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.